Get the Stockscreener App
11.88
2.78%
-0.34
After Hours:
11.47
-0.41
-3.45%
Bioventus Inc stock is traded at $11.88, with a volume of 634.02K.
It is down -2.78% in the last 24 hours and up +31.27% over the past month.
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
See More
Previous Close:
$12.22
Open:
$12.06
24h Volume:
634.02K
Relative Volume:
1.00
Market Cap:
$804.85M
Revenue:
$568.09M
Net Income/Loss:
$27.27M
P/E Ratio:
36.26
EPS:
0.3276
Net Cash Flow:
$71.41M
1W Performance:
+13.36%
1M Performance:
+31.27%
6M Performance:
+47.95%
1Y Performance:
+60.76%
1-Day Range:
$11.58
$12.08
1-Week Range:
$10.49
$12.30
52-Week Range:
$5.81
$12.30
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
11.88 | 804.85M | 568.09M | 27.27M | 71.41M | 0.3276 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | CJS Securities | Market Outperform |
| Feb-09-26 | Initiated | Barrington Research | Outperform |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Bioventus (BVS) Stock Looks Overvalued On Earnings Yet Backed By Broader Checks - Yahoo Finance
Bioventus, Inc. Class A Actuals & Estimates (LSX:A2APNA) - TradingView
Are You Looking for a Top Momentum Pick? Why Bioventus (BVS) is a Great Choice - Yahoo Finance
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $16 - Moomoo
Wall Street Analysts Predict a 28.81% Upside in Bioventus (BVS): Here's What You Should Know - Yahoo Finance
Bioventus Deadline Alert - TMX Newsfile
A2APNA Forecast — Price Target — Prediction for 2027 - TradingView
A2APNA Stock Price and Chart — LSX:A2APNA - TradingView
Bioventus: I See A Better Business Trading At A Fair Price (Upgrade) (NASDAQ:BVS) - Seeking Alpha
BioventusTargeting Earnings Growth Outpacing Revenue Growth In 2026 - RTTNews
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock? - Yahoo Finance
Zacks.com featured highlights include First Advantage, Bioventus and Ooma - Yahoo Finance
Bioventus shares rise after Medicare reverses reimbursement cuts By Investing.com - Investing.com South Africa
Bioventus shares rise after Medicare reverses reimbursement cuts - Investing.com
Bioventus Shareholder Action Reminder - TMX Newsfile
Total liabilities of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Free cash flow of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Cash flow from investing activities of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Net debt of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Non-operating income (total) of Bioventus, Inc. Class A – LS:A2APNA - TradingView
EBIT of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Cash flow from operating activities of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Operating income of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Preferred dividends of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Bioventus, Inc. Class A Cash Flow – LS:A2APNA - TradingView
Non-controlling/minority interest of Bioventus, Inc. Class A – LS:A2APNA - TradingView
EBITDA of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Debt to assets ratio of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Debt to equity ratio of Bioventus, Inc. Class A – LS:A2APNA - TradingView
EBIT per share of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Price to earnings forward of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Enterprise value to EBITDA forward of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Return on equity % of Bioventus, Inc. Class A – LS:A2APNA - TradingView
CapEx per share of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Net current asset value per share of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Enterprise value of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Net margin % of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Enterprise value to EBITDA ratio of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Inventory turnover of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Enterprise value to EBIT forward of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Price to cash flow ratio of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Diluted shares outstanding of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Return on invested capital % of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Total debt per share of Bioventus, Inc. Class A – LS:A2APNA - TradingView
EBITDA margin % of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Quick ratio of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Diluted earnings per share (diluted EPS) of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Net income before discontinued operations of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Bioventus, Inc. Class A Dividends – LS:A2APNA - TradingView
Cost of goods sold of Bioventus, Inc. Class A – LS:A2APNA - TradingView
Bioventus, Inc. Class A Earnings and Revenue – LS:A2APNA - TradingView
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):